Rx-360’s New SCAR Guide Streamlines Supplier Corrective Actions

Download the SCAR Guide + Blank Form for Free at Rx-360.org Rx-360 has released a new guide called “SCAR – Supplier Corrective Action Report Programs: A Practical Guide.” This guide helps professionals manage improvements they need from suppliers and vendors. These improvements are based on regulations and the company's own quality standards. You can download […]

Silvaco Reports Second Quarter 2025 Financial Results

(NASDAQ:SVCO), Achieved Gross Bookings of $12.91 Million and Revenue of $12.05 Million Landed 10 New Logos in Photonics, Automotive, Military, Foundry, and Power Achieved Trailing Twelve-Month ACV Growth of 26% SANTA CLARA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco” or the “Company”), a provider of TCAD, EDA software, and

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

(NASDAQ:CPRX), Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior Year Reaffirms Full-Year 2025 Total Revenue Guidance of $545 Million to $565 Million, Reflecting Broad-Based Growth and Sustained

Silvaco Reports Second Quarter 2025 Financial Results

Silvaco Reports Second Quarter 2025 Financial Results GlobeNewswire August 06, 2025 Achieved Gross Bookings of $12.91 Million and Revenue of $12.05 Million Landed 10 New Logos in Photonics, Automotive, Military, Foundry, and Power Achieved Trailing Twelve-Month ACV Growth of 26% SANTA CLARA, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) — Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco”

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update

Catalyst Pharmaceuticals Reports Record Second Quarter and First Half 2025 Financial Results; Provides Business Update GlobeNewswire August 06, 2025 Achieved Record Q2 2025 Total Revenues of $146.6 Million, an Increase of 19.4% YoY, Marking Another Quarter of Consecutive Growth Reported Record First Half 2025 Total Revenues of $288.0 Million, an Increase of 30.2% Over Prior

Gladstone Commercial Corporation Reports Results for the Second Quarter Ended June 30, 2025

Please note that the limited information that follows in this press release is not adequate to make an informed investment judgment. MCLEAN, VA / ACCESS Newswire / August 6, 2025 / Gladstone Commercial Corporation (Nasdaq:GOOD) ("Gladstone Commercial" or the "Company") today reported financial results for the second quarter ended June 30, 2025. A description of

NHI Issues Investor Update

MURFREESBORO, TN / ACCESS Newswire / August 6, 2025 / National Health Investors, Inc. (NYSE:NHI) has issued the following investor update which can be found at: https://investors.nhireit.com/News/presentations-and-webcasts/default.aspx About NHI Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale, leasebacks, joint-ventures, senior housing operating partnerships, and mortgage

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

(NASDAQ:CNTX), CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results GlobeNewswire August 06, 2025 CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027 PHILADELPHIA, Aug. 06, 2025 (GLOBE NEWSWIRE) —

Scroll to Top